Journal

A dated UK and European availability guide separates Heidi and Tandem product claims, purchasing routes, integrations and announced future capabilities.

Heidi's September 2026 financing combines equity and growth investment, but clinicians should distinguish investment plans from available products.

Compare OpenEvidence and iatroX by access, licensed sources, jurisdiction, follow-up learning and the exact clinical task.

Three fictional prescribing cases distinguish missing information, uncertainty about the next step and situations where a prescription is not the answer.

Learn how to interpret CredibleMeds categories, distinguish medicine classifications from patient risk and document a focused prescribing review.

Combine official prescribing-assessment preparation with free question practice and decide when a paid PSA resource adds value.

Tortus and X-on illustrate why NHS workflow integration may be a credible competitive response to expansion, provided its benefits survive practical deployment.

Updated September 2026 analysis of how Heidi, TORTUS and other rivals can respond to Tandem through workflow depth, partnerships and demonstrable customer value.

Accurx Scribe uses Tandem technology, but Sovereign Health does not establish an automatic change to every NHS deployment. Check the contract, configuration and local approval.

Compare Ask Tandem and Ask-iatroX by evidence access, patient context, standalone use and learning, including Tandem's latest product updates.

Compare dated funding milestones for Tandem, Heidi, OpenEvidence and Abridge, and the different clinical problems their investment plans address.

Interpret Heidi's Metro South Health pilot figures accurately, separating staff-reported benefits, planned access and evidence about documentation quality.